Malaysian hospital giant IHH Healthcare has named India a high-priority growth market and plans to elevate its stake in Fortis Healthcare to 50 percent over the medium term. Group CEO Prem Kumar Nair emphasized that this expansion aims to position IHH among India's top three private healthcare players by 2030, with bed capacity reaching 10,000. Legal hurdles from past tender offers now resolved, the group commits ₹2,500 crore in capital expenditure for brownfield projects and integrations.
Fortis Turnaround Fuels Strategic Confidence
IHH entered Fortis at ₹170 per share in fiscal 2019, a move Nair credits with perfect timing as the stock now trades near ₹800 and has peaked at ₹1,000. From a loss-making entity, Fortis has transformed into a profitable operation with 23-24 percent EBITDA margins, revenue growth in the mid-teens, and EBITDA expansion at mid-20s percent annually over five to six years. Hospital numbers have risen from 27 to 36, incorporating Gleneagles facilities, while clinical quality matches or surpasses IHH's global standards in Malaysia, Singapore, and Turkey.
Quality Over Quantity in Expansion Drive
Nair rejects sheer bed proliferation, preferring fewer high-quality, intensive-care beds to 15,000 low-standard ones. Growth centers on existing clusters in Punjab, Jalandhar, Bengaluru's People Tree, and NCR's Manesar, alongside Gleneagles integration. IHH's board visited Fortis sites this week, signaling deep commitment, as the group eyes accretive earnings per share from higher Fortis ownership despite its current 31 percent stake.
Diversification into Diagnostics and Ambulatory Care
The diagnostics arm, once SRL then briefly Agilus, reverted to SRL after a ₹50 crore rebranding detour, now thriving with strong margins and a pivot to high-end genomics and precision medicine. Fortis hospitals enable tandem operations, enhancing patient outcomes where rivals lack integrated facilities. IHH advances ambulatory procedures like knee replacements, spinal work, cardiac interventions, and chemotherapy outside inpatient settings to cut costs, while a "true cost project" scrutinizes billing for efficiency savings passed to patients.
Oncology and Equipment Investments Ahead
Oncology emerges as a priority, with Fortis's FMRI hosting India's first MR-Linac machine; group-wide procurement secures better pricing. This measured approach contrasts rivals' aggressive bed additions, positioning IHH as a clinical leader in a market demanding both profitability and excellence. Medium-term goals hinge on sustained quality amid India's booming private healthcare demand.
